Risedronate Sodium · RISEDRONATE SODIUM 35 mg/1 · Tablet, Delayed Release · Oral · Sun Pharmaceutical Industires Inc.
NDC 63304-0440-09 · 1 DOSE PACK in 1 CARTON / 4 TABLET, DELAYED RELEASE in 1 DOSE PACK · ANDA · View full market →
Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The generic price is up 11% over the past year, to $25.10 per unit. The brand (Atelvia) runs $63.85 per unit — 2.1× more. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Some pressure is visible, but not much — here’s everything the score found to count.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Allergan, Inc. | RISEDRONATE SODIUM HEMI-PENTAHYDRATE 30.1 mg/1; RISEDRONATE SODIUM MONOHYDRATE 4.9 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Allergan, Inc. | RISEDRONATE SODIUM HEMIPENTAHYDRATE 30.1 mg/1; RISEDRONATE SODIUM MONOHYDRATE 4.9 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Pharmaceuticals, Inc. | RISEDRONATE SODIUM HEMIPENTAHYDRATE 30.1 mg/1; RISEDRONATE SODIUM MONOHYDRATE 4.9 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Sun Pharmaceutical Industires Inc. | RISEDRONATE SODIUM 35 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Risedronate Sodium — NDC 63304-0440-09," retrieved September 3, 2026, https://drugdashboards.com/drug/63304044009.
Free to cite with attribution — see how the data is put together.